BeOne Medicines (ONC) Proxy filing summary

Executive summary

• Achieved GAAP profitability and strong cash flow in 2025, with 40% revenue growth to $5.3B and net income of $287M, marking a turnaround from prior losses.

• Completed redomiciliation to Switzerland and rebranded, reflecting a global footprint and commitment to oncology innovation.

• Expanded patient reach, with over two million treated and a workforce of nearly 12,000 across six continents.

• Advanced leading therapies in CLL, including BRUKINSA, sonrotoclax, and BTK CDAC, with significant regulatory milestones and market expansion.

• Deep and diverse clinical pipeline with multiple solid tumor and hematologic programs expected to reach key milestones in 2026.

Voting matters and shareholder proposals

• 20 proposals for shareholder action, including approval of financial statements, discharge of directors, election/re-election of directors and committee members, auditor appointments, compensation approvals, share plan amendments, share issuance and repurchase mandates, and authorization for Amgen to maintain its shareholding.

• Board recommends voting FOR all proposals and director nominees.

• Shareholders can vote in person, electronically, or by proxy, with detailed instructions for various share classes and geographies.

Board of directors and corporate governance

• Board to be reduced to 10 members, with a majority independent under Nasdaq and HK Listing Rules.

• Nominees include a mix of experienced executives, scientists, and financial experts, with three female directors and strong diversity in skills and backgrounds.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, Scientific Advisory, and Commercial and Medical Affairs Advisory Committees.

• Lead Independent Director role established for enhanced governance.